Szostak M Anne's Form 4 filing
IDEXX Laboratories Inc (IDXX) · filed Sep 9, 2024
- Accession no.
- 0000874716-24-000131
- Filed
- Sep 9, 2024
- Trade date
- Sep 5-6, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $234.7K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Szostak M AnneCIK 0001094176 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 5, 2024 | Common Stock | GGiftDisposed | −500 | $0.00 | $0 | 6,061 | Indirect | |
| Sep 5, 2024 | Common Stock | GGiftAcquired | +500 | $0.00 | $0 | 500 | Indirect | |
| Sep 6, 2024 | Common Stock | SSaleDisposed | −500 | $469.37F3 | −$234,685 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average price of the shares sold ranging from a low of $468.98 to a high of $469.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.